In addition to kinase inhibitors, other approaches are being developed to target LRRK2, including antisense oligonucleotides and proteolysis-targeting chimeras [22–24], all with the collective goal of reducing LRRK2 protein and/or its activity to determine whether this will ameliorate PD pathology. Here, LRRK2 is linked to Parkinson disease.